Engrossed
Underlined text would be added to current law. Struck-through text would be removed.
| By: Paxton, et al. | S.B. No. 883 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to patient access to prescription drugs for off-label use | |
| for COVID-19 treatment. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. (a) This Act shall be known as the Right to Treat | |
| Act. | |
| (b) The legislature finds that: | |
| (1) the relationship between a physician and patient | |
| is valued; | |
| (2) during the COVID-19 pandemic, many patients have | |
| been frustrated to learn that their physicians are discouraged from | |
| prescribing for off-label use prescription drugs that may aid in | |
| the patient's treatment of and recovery from COVID-19; and | |
| (3) this Act is intended to enable a patient to access | |
| and a physician to prescribe for off-label use prescription drugs | |
| that may aid in the patient's treatment of and recovery from | |
| COVID-19. | |
| SECTION 2. Subtitle C, Title 6, Health and Safety Code, is | |
| amended by adding Chapter 491 to read as follows: | |
| CHAPTER 491. OFF-LABEL USE OF PRESCRIPTION DRUGS FOR COVID-19 | |
| TREATMENT | |
| Sec. 491.001. DEFINITIONS. In this chapter: | |
| (1) "COVID-19" means the 2019 novel coronavirus | |
| disease. | |
| (2) "Off-label use" means the use of a prescription | |
| drug approved for use by the United States Food and Drug | |
| Administration in a manner other than the approved use. | |
| (3) "Physician" means an individual licensed to | |
| practice medicine in this state. | |
| Sec. 491.002. APPLICABILITY. This chapter applies only to | |
| the prescribing of a prescription drug the United States Food and | |
| Drug Administration has approved for human use. | |
| Sec. 491.003. PROHIBITED STATE INTERFERENCE WITH PATIENT | |
| ACCESS TO OFF-LABEL USE OF PRESCRIPTION DRUG. An official, | |
| employee, or agent of this state may not prohibit or restrict a | |
| physician from prescribing for off-label use a prescription drug to | |
| treat a patient who is exposed to or diagnosed with COVID-19. | |
| Sec. 491.004. NO CAUSE OF ACTION CREATED. This chapter does | |
| not create a private or state cause of action against a manufacturer | |
| of a prescription drug approved by the United States Food and Drug | |
| Administration or against a physician or any other person involved | |
| in the care of a patient who is exposed to or diagnosed with | |
| COVID-19 for any harm to the patient resulting from the off-label | |
| use of the drug in the treatment of COVID-19. | |
| Sec. 491.005. PROHIBITED ACTION AGAINST PHYSICIAN'S | |
| LICENSE. Notwithstanding any other law, the Texas Medical Board | |
| may not revoke, fail to renew, suspend, or take any other adverse | |
| action against a physician's license under Subchapter B, Chapter | |
| 164, Occupations Code, based solely on the physician's prescribing | |
| a prescription drug for off-label use to treat a patient who is | |
| exposed to or diagnosed with COVID-19, provided the physician's | |
| treatment of the patient meets the medical standard of care. | |
| SECTION 3. This Act takes effect immediately if it receives | |
| a vote of two-thirds of all the members elected to each house, as | |
| provided by Section 39, Article III, Texas Constitution. If this | |
| Act does not receive the vote necessary for immediate effect, this | |
| Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.